Related Experiment Video
Updated: Mar 7, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
1.4K
Topiramate and accommodation: Does topiramate cause accommodative dysfunction?
Eren Çerman1, Semra Akkaya Turhan1, Muhsin Eraslan1
1Marmara University School of Medicine, Department of Ophthalmology, Istanbul, Turkey.
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie
|February 27, 2017
Summary
Topiramate users exhibit increased accommodative lag, a measure of focusing ability, compared to controls. This visual dysfunction, particularly noticeable at various stimulus levels, may contribute to reported visual symptoms in patients taking topiramate.
Area of Science:
- Ophthalmology
- Neuroscience
- Pharmacology
Background:
- Topiramate is an anticonvulsant and migraine prophylactic medication.
- Visual disturbances are potential side effects of topiramate.
- Accommodation is the eye's ability to change focus.
Purpose of the Study:
- To investigate the impact of topiramate on the accommodation function.
- To compare accommodative function between topiramate users and a control group.
Main Methods:
- A case-control clinical study was conducted.
- Participants included 22 topiramate users (100 mg/kg) and 16 controls.
- Dynamic refraction measurements were taken using a WAM-5500 refractometer at various accommodation stimuli.
Main Results:
- Topiramate users showed significantly higher accommodative lag at 0 D, 2.5 D, 3 D, and 5 D stimuli.
- Accommodation stimulus and topiramate use were the primary drivers of accommodative lag.
- Age and accommodation stimulus were the strongest predictors of accommodative lag.
Conclusions:
- Accommodative lag is significantly greater in topiramate users, even after accounting for age.
- The observed accommodative lag may be linked to the visual symptoms experienced by patients using topiramate.
More Related Videos
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
646
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
646
01:28Drug Therapy
346
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
346
01:14Antiepileptic Drugs: Glutamate Antagonists
1.1K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:20Antiepileptic Drugs: Potassium Channel Activators
873
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
873
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.0K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K